4.6 Article

Genetic Variants in the Fat and Obesity Associated (FTO) Gene and Risk of Alzheimer's Disease

期刊

PLOS ONE
卷 7, 期 12, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0050354

关键词

-

资金

  1. National Institutes of Health (NIH)
  2. National Institute on Aging [R37-AG15473, P01-AG07232]
  3. Blanchett Hooker Rockefeller Foundation
  4. Paul B. Beeson Career Development Award [K23AG034550]
  5. National Institute on Aging - Late Onset Alzheimer's Disease Family Study [U24AG026390]
  6. National Cell Repository for Alzheimer's Disease (NCRAD) [U24 AG21886]
  7. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  8. National Institute of Biomedical Imaging and Bioengineering
  9. Canadian Institutes of Health Research
  10. Northern California Institute for Research and Education
  11. NIH [P30 AG010129, K01 AG030514]
  12. Dana Foundation
  13. National Institute on Aging (NIA)
  14. Abbott
  15. Amorfix Life Sciences Ltd.
  16. AstraZeneca
  17. Bayer HealthCare
  18. BioClinica, Inc.
  19. Biogen Idec Inc.
  20. Bristol-Myers Squibb Company
  21. Eisai Inc.
  22. Elan Pharmaceuticals Inc.
  23. Eli Lilly and Company
  24. F. Hoffmann-La Roche Ltd
  25. GE Healthcare
  26. Innogenetics, N.V.
  27. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  28. Johnson & Johnson Pharmaceutical Research & Development LLC.
  29. Medpace, Inc.
  30. Merck Co., Inc.
  31. Meso Scale Diagnostics, LLC.
  32. Novartis Pharmaceuticals Corporation
  33. Pfizer Inc.
  34. Servier
  35. Synarc Inc.
  36. Takeda Pharmaceutical Company

向作者/读者索取更多资源

Background: Recent studies showed that polymorphisms in the Fat and Obesity-Associated (FTO) gene have robust effects on obesity, obesity-related traits and endophenotypes associated with Alzheimer's disease (AD). Methods: We used 1,877 Caucasian cases and controls from the NIA-LOAD study and 1,093 Caribbean Hispanics to further explore the association of FTO with AD. Using logistic regression, we assessed 42 SNPs in introns 1 and 2, the region previously reported to be associated with AD endophenotypes, which had been derived by genome-wide screenings. In addition, we performed gene expression analyses of neuropathologically confirmed AD cases and controls of two independent datasets (19 AD cases, 10 controls; 176 AD cases, 188 controls) using within-and between-group factors ANOVA of log(10) transformed rank invariant normalized expression data. Results: In the NIALOAD study, one SNP was significantly associated with AD and three additional markers were close to significance (rs6499640, rs10852521, rs16945088, rs8044769, FDR p-value: 0.05 <0.09). Two of the SNPs are in strong LD (D'>0.9) with the previously reported SNPs. In the Caribbean Hispanic dataset, we identified three SNPs (rs17219084, rs11075996, rs11075997, FDR p-value: 0.009 <0.01) that were associated with AD. These results were confirmed by haplotype analyses and in a metaanalysis in which we included the ADNI dataset. FTO had a significantly lower expresssion in AD cases compared to controls in two independent datasets derived from human cortex and amygdala tissue, respectively (p = 2.18x10-5 and p<0.0001). Conclusions: Our data support the notion that genetic variation in Introns 1 and 2 of the FTO gene may contribute to AD risk.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据